[go: up one dir, main page]

MX2022001488A - Composicion inmunogenica. - Google Patents

Composicion inmunogenica.

Info

Publication number
MX2022001488A
MX2022001488A MX2022001488A MX2022001488A MX2022001488A MX 2022001488 A MX2022001488 A MX 2022001488A MX 2022001488 A MX2022001488 A MX 2022001488A MX 2022001488 A MX2022001488 A MX 2022001488A MX 2022001488 A MX2022001488 A MX 2022001488A
Authority
MX
Mexico
Prior art keywords
immunogenic composition
immunogenic
aecopd
prevention
human
Prior art date
Application number
MX2022001488A
Other languages
English (en)
Inventor
Vincent Edwin Paul Levet
Frédéric Stéphane Mathot
Bram Vuylsteke
Ghislain Delpierre
Juliette Fortpied
Virginie Hellebaut
Roland Mainil
Aira Maria Dolores Morales
Philippe Scieur
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2022001488A publication Critical patent/MX2022001488A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con composiciones inmunogénicas que comprenden polipéptidos inmunogénicos de Haemophilus influenzae y Moraxella catarrhalis y su uso en el tratamiento o prevención de una exacerbación aguda de la enfermedad pulmonar obstructiva crónica (AEEPOC) en un sujeto, por ejemplo, un humano.
MX2022001488A 2019-08-05 2020-08-03 Composicion inmunogenica. MX2022001488A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19189963 2019-08-05
PCT/EP2020/071760 WO2021023691A1 (en) 2019-08-05 2020-08-03 Immunogenic composition

Publications (1)

Publication Number Publication Date
MX2022001488A true MX2022001488A (es) 2022-03-02

Family

ID=67658431

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001488A MX2022001488A (es) 2019-08-05 2020-08-03 Composicion inmunogenica.

Country Status (9)

Country Link
US (1) US20230066762A1 (es)
EP (1) EP4010014A1 (es)
JP (1) JP2022543281A (es)
CN (1) CN114667158A (es)
AU (1) AU2020325645A1 (es)
BR (1) BR112021026565A2 (es)
CA (1) CA3148924A1 (es)
MX (1) MX2022001488A (es)
WO (1) WO2021023691A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022175423A1 (en) * 2021-02-22 2022-08-25 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
WO2023194971A2 (en) * 2022-04-08 2023-10-12 St. Jude Children's Research Hospital Immunogenic compositions and methods for reducing transmission of pathogens
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
DK0812593T4 (da) 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
PT772619E (pt) 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CZ303653B6 (cs) 1999-03-19 2013-01-30 Smithkline Beecham Biologicals S. A. Imunogenní prostredek
ES2298269T3 (es) 2000-09-26 2008-05-16 Idera Pharmaceuticals, Inc. Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales.
AU2006277076B2 (en) 2005-08-10 2012-03-29 Arne Forsgren Ab Interaction of Moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
CN101374859B (zh) 2006-01-17 2014-11-26 阿恩·福斯格伦 新的表面外露流感嗜血菌蛋白质(蛋白质E；pE)
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018178264A1 (en) * 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment

Also Published As

Publication number Publication date
CN114667158A (zh) 2022-06-24
US20230066762A1 (en) 2023-03-02
BR112021026565A2 (pt) 2022-05-03
JP2022543281A (ja) 2022-10-11
AU2020325645A1 (en) 2022-02-17
WO2021023691A1 (en) 2021-02-11
CA3148924A1 (en) 2021-02-11
EP4010014A1 (en) 2022-06-15

Similar Documents

Publication Publication Date Title
MX2022001488A (es) Composicion inmunogenica.
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
MX2021010868A (es) Bacteria de la familia christensenellaceaeas en la prevencion y/o tratamiento de enfermedades inflamatorias cronicas y/o enfermedades gastrointestinales inflamatorias y/o canceres.
GB202015827D0 (en) 4'-halogen containing nucleotide and nucleotide therapeutic compositions and uses related thereto
IL286467A (en) Methods for producing biological conjugates of polysaccharides e. coli o - antigen, their preparations and methods of using them
MX2019000346A (es) Metodos y composiciones para el tratamiento del cancer.
SG11202011296VA (en) Compositions and methods for the treatment of parkinson's disease
PH12022550539A1 (en) Therapeutic fusion proteins
MX2019012086A (es) Composiciones y métodos para tratar o prevenir trastornos relacionados con la permeabilidad intestinal.
IL283469A (en) Inhalable preparations for use in the treatment of lung diseases
MY205028A (en) Protein for treatment of inflammatory diseases
MY191930A (en) Microbial lysozyme for use in the treatment of irritable bowel syndrome or inflammatory bowel disease
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
MX2020001820A (es) Metodos para reforzar las respuestas inmunitarias.
PH12020500489A1 (en) Methods and compositions for treating chronic lung diseases
MX2021002012A (es) Metodos de tratamiento del trastorno por estres agudo y trastorno por estres postraumatico.
IL277632A (en) CDNF fragments from the carboxyl end, pharmaceutical compositions containing them and their uses
WO2017049082A3 (en) Compositions comprising pregnancy specific glycoproteins and methods of use thereof
MX2022001489A (es) Proceso para la preparacion de una composicion que comprende un polipeptido de proteina d.
MX2010006408A (es) Prevencion y tratamiento de la otitis media utilizando leche enriquecida con iga.
AU2018244677A1 (en) Antibody binding specifically to N-terminal region of lysyl-tRNA synthetase exposed on cell membrane
MX2023014655A (es) Formas cristalinas de trofinetida.
MX2022000847A (es) Dosificacion para la prevencion o tratamiento de la enfermedad de injerto contra huesped (gvhd) con proteinas de fusion il-22 fc.
MX2019002647A (es) Composiciones de tesofensina.
WO2020118199A3 (en) Compositions and methods for treating or preventing nash, nafld, diabetes, atherosclerosis, and/or obesity